Compendium of Cancer Genome Aberrations

CNS5:Volunteer Assignments and Opportunities: Difference between revisions

← Older edit
VisualWikitext
No edit summary
m due date
 
(16 intermediate revisions by 4 users not shown)
Line 121: Line 121:
|Laveniya Satgunaseelan
|Laveniya Satgunaseelan
|
|
|12/06/2025
|
|PENDING
|COMPLETE
|
|
|LS
|LS
Line 174: Line 174:
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|Disease
|Disease
|Layla Zhu
|<br />3/2/2026
|
|
|<br />
|PENDING
|
|
|
|
|LS
|LS
Line 185: Line 185:
|[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]]
|[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]]
|Disease
|Disease
|Wahab Khan
|2/8/2026
|
|
|
|PENDING
|
|
|
|
|
|
Line 199: Line 199:
|15/04/2025
|15/04/2025
|
|
|PENDING - email reminder 9/4/2025
|COMPLETE
|
|2/8/2026 (Feb 8)
|LS
|LS
|
|
Line 229: Line 229:
|[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]]
|[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]]
|Disease
|Disease
|Milana.Djonovic (trainee), Laveniya/Madina
|4/26/2026
|6/15/2026
|PENDING
|
|
|
|LS
|
|
|
|
|
|
|
|
Line 416: Line 416:
|[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]]
|[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]]
|Disease
|Disease
|Laveniya Satgunaseelan
|2/4/2026
|30/6/2026
|PENDING
|
|
|
|
|
|
|
|
|
|-
|
|[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]]
|
|Disease
|
|Laveniya Satgunaseelan
|-
|2/4/2026
|[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]]
|30/6/2026
|Disease
|PENDING
|
|
|
|
|
|
|
|
Line 438: Line 438:
|[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]]
|[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 635: Line 635:
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|Disease
|Disease
|Hannah Wollenzien
|1/11/2026
|
|
|Pending
|
|
|
|MS
|
|
|
|
|
|
|
Line 801: Line 801:
|Fang Fang (trainee)+Katie Schieffer (mentor)
|Fang Fang (trainee)+Katie Schieffer (mentor)
|11/19/2025
|11/19/2025
|
|6/15/2026
|Pending
|Pending
|
|
Line 853: Line 853:
|[[CNS5:Schwannoma|Schwannoma]]
|[[CNS5:Schwannoma|Schwannoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Neurofibroma|Neurofibroma]]
|[[CNS5:Neurofibroma|Neurofibroma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Perineurioma|Perineurioma]]
|[[CNS5:Perineurioma|Perineurioma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]]
|[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]]
|[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 919: Line 919:
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 994: Line 994:
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,060: Line 1,060:
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,082: Line 1,082:
|[[CNS5:Ewing_sarcoma|Ewing sarcoma]]
|[[CNS5:Ewing_sarcoma|Ewing sarcoma]]
|Disease
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|
|
|
|
|
|-
|[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]]
|[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,223: Line 1,223:
|[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]]
|[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]]
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]]
|
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|-
|[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]]
|[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]]
|Disease
|Disease
|
|
Line 1,243: Line 1,265:
|
|
|-
|-
|[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]]
|[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]]
|Disease
|Disease
|Jennie Thurston
|Jennie Thurston
Line 1,289: Line 1,289:
|[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]]
|[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]]
|[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,333: Line 1,333:
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]]
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|
|
====CHAPTER 11 (GERM CELL TUMOURS)====
|
|
----
|
|
----
|
|
|
----
|
|-
|[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]]
|Disease
|
|
|
|
|
|
|
|
|-
|
====CHAPTER 11 (GERM CELL TUMOURS)====
|
----
|
----
|
----
|
|
----
----
Line 1,545: Line 1,545:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
Line 1,556: Line 1,556:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,578: Line 1,578:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 1,601: Line 1,600:
|N/A
|N/A
|N/A
|N/A
|
|-
|-
!'''Disease'''
!'''Disease'''
Line 1,615: Line 1,615:
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|Disease
|Disease
|[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
Line 1,623: Line 1,622:
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
Line 1,633: Line 1,633:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
Line 1,644: Line 1,644:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]]
|
|
|
|
|
|-
|[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Carney_complex|Carney complex]]
|[[CNS5:Carney_complex|Carney complex]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,688: Line 1,688:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]]
|[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,730: Line 1,730:
!'''Author Content (Pending or Complete)'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Date of Last Editor Review'''
!'''Notes'''
!'''Notes'''
|-
|-
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 1,754: Line 1,765:
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|Disease
|
|
|
|
|
|
|
|
|
|-
|-
|}
|}
Retrieved from "https://content.ccga.io/index.php/CNS5:Volunteer_Assignments_and_Opportunities"